Larimar Therapeutics
LRMR
56 hedge funds and large institutions have $62.9M invested in Larimar Therapeutics in 2017 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 16 increasing their positions, 19 reducing their positions, and 9 closing their positions.
2,133% more call options, than puts
Call options by funds: $67K | Put options by funds: $3K
34% more capital invested
Capital invested by funds: $47M → $62.9M (+$15.9M)
0.07% more ownership
Funds ownership: 4.05% → 4.12% (+0.07%)
10% less funds holding
Funds holding: 62 → 56 (-6)
16% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 19
56% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$2.09M |
| 2 |
RA
Royce & Associates
New York
|
+$811K |
| 3 |
NC
Nexthera Capital
New York
|
+$644K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$390K |
| 5 |
Bank of New York Mellon
New York
|
+$191K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$829K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$581K |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$458K |
| 4 |
SIM
Spark Investment Management
New York
|
-$454K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$369K |
LRMR Hedge Fund Activity: Q4 2017 in Review
56 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Larimar Therapeutics (LRMR) for Q4 2017, worth a combined $62.9M — up 34% from $47M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of LRMR and 4 opened new positions — a net loss of 5 holders — while 19 trimmed existing stakes and 16 added.
The largest buyer was Armistice Capital, adding an estimated $2.09M. The largest seller was Millennium Management, cutting an estimated $829K.
- 56 institutional investors held Larimar Therapeutics (LRMR) as of Q4 2017, down from 62 in Q3 2017.
- Funds reported $62.9M of Larimar Therapeutics stock for Q4 2017, up 34% quarter-over-quarter.
- 4 funds opened new Larimar Therapeutics positions in Q4 2017 and 9 closed out, a net change of -5 holders.
- The largest Larimar Therapeutics buyer in Q4 2017 was Armistice Capital, an estimated $2.09M added.
- The largest Larimar Therapeutics seller in Q4 2017 was Millennium Management, an estimated $829K sold.
Based on aggregated 13F filings for Q4 2017.